Yoshinobu Onuma; Patrick W Serruys， The ABSORB Investigators
　　Thorax Cntr， Erasmus MC， Rotterdam， Netherlands
　　Background: Bioabsorbable polymer drug-eluting stents (DES) are an alternative approach potentially providing short-term vessel scaffolding combined with drug delivery capability but avoiding the long-term limitations of metallic stents， such as late stent thrombosis and impaired endothelial function. Two-year follow-up of this first-in-man trial using the BVS Everolimus-Eluting Stent System (Abbott Vascular， Santa Clara， CA， USA) demonstrated an in-stent late loss of 0.48mm and diameter stenosis of 27%. The two-year optical coherent tomography and intravascular ultrasound imaging analysis demonstrated luminal area enlargement compared to 6 months， due to a decrease in plaque without change in vessel size. In addition， vasomotion was restored at the stented site and adjacent coronary artery at 2 years. However， the clinical outcomes beyond 2 years after implantation of the BVS stents are not yet available.
　　Methods: The purpose of the ABSORB Clinical Investigation is to assess the safety and performance of the BVS Everolimus-Eluting Coronary Stent System (Abbott Vascular， Santa Clara， CA， USA) in the treatment of patients with a single de novo native coronary artery lesion. Ischemia driven major adverse cardiac events (ID-MACE) was defined as a composite of cardiac death， myocardial infarction， or ischemia-driven target lesion revascularization.
　　Results: Enrolment of 30 patients at 4 clinical sites in Europe and New Zealand was completed in July 2006. At 2 years one patient died from non-cardiac cause at 706 days post-procedure. The mean duration of follow-up was 740.9 days (minimum 707 days， maximum 800 days). At 2 year follow-up， there was one non-Q wave myocardial infarction (peak troponin 2.21ng/ml) related to the treatment of a non-flow-limiting stenosis (QCA DS 42%) in a patient who experienced a single episode of angina at rest without electrographic evidence of ischemia.
　　Conclusion: Results up to 2 years indicate that the BVS stent has a low long-term MACE rate (3.6%). Clinical results at 3 years are being collected and will be presented.